The impact of cigarette dependence severity on disease outcomes and depression in ankylosing spondylitis

Abstract

Introduction: Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease. Smoking plays a role in AS pathogenesis and causes difficulties in its treatment. The aim of this study is to investigate the association of disease activity, functional status, spinal mobility, depression, chest expansion, pain, fatigue, quality of life, respiratory function with cigarette dependence severity in patients with AS.

Methods: The study included 71 patients diagnosed as AS. Patients were evaluated on questionnaires and examination scales specific to assessment of AS. The results were compared using the SPSS-23 software.

Results: Out of the total 71 patients, 40 (56.3%) were smokers, 31 (43.7%) were non-smokers. There were no significant differences between the smokers and the non-smokers with respect to the median values in Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Functional Index, Ankylosing Spondylitis Quality of Life questionnaire, Short Form 36 (SF-36), chest expansion, the fingertip-to-floor test and Beck Depression Inventory (p > 0.05). However, there were significant differences when comparing the median scores on BASMI (p = 0.036), SF-36 physical role strength (p = 0.004) and the chest expansion (p = 0.015) of the smoker patients placed in the three Fagerström Test for Nicotine Dependence (FTND) subgrouping.

Conclusion: AS patients with smoking have elevated FTND scores and worse values for test of disease activity and quality of life.

Keywords

• Smoking,ankylosing spondylitis,life quality

References

1. [1] Zhang S, Li Y, Deng X, Huang F. Similarities and differences between spondyloarthritis in Asia and other parts of the World. Curr Opin Rheumatol 2011;23:334-8.
2. [2] O’Dwyer T, Monaghan A, Moran J, O'Shea F, Wilson F. Behaviour change intervention increases physical activity, spinal mobility and quality of life in adults with ankylosing spondylitis: a randomised trial. J Physiother 2017;63:30-9.
3. [3] Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90.
4. [4] Braun J, Brandt J, Listing J, Alten R, Golder W, Gromnica-Ihle E, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
5. [5] Videm V, Cortes A, Thomas R, Brown MA. Current smoking is associated with incident ankylosing spondylitis--the HUNT population-based Norwegian health study. J Rheumatol 2014;41:2041-8.
6. [6] Wendling D, PratiC. Spondyloarthritis and smoking: towards a new insight into the disease. Expert Rev Clin Immunol 2013;9:511-6.
7. [7] Mattey DL, Dawson SR, Healey EL, Packham JC. Relationshipbetween smoking and patient-reported measures of disease outcome in ankylosing spondylitis. J Rheumatol 2011;38:2608-15.
8. [8] Zhao S, Challoner B, Khattak M, Moots RJ, Goodson NJ. Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. Rheumatol Int 2017;37:239-44.

9. [9] Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 1999;38:878-82.
10. [10] Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
11. [11] Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
12. [12] Nemeth R, Smith F, Elswood J, Calin A. Ankylosing spondylitis - an approach to measurement of severity and outcome: ankylosing spondylitis assessment questionnaire (ASAQ) - a controlled study. Br J Rheumatol 1987;26 (suppl 1):69-70.
13. [13] Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20-6.
14. [14] McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
15. [15] Moll JM, Wright V. An objective clinical study of chest expansion. Ann Rheum Dis 1972;31:1-8.
16. [16] Ekedahl H, Jönsson B, Frobell RB. Fingertip-to-floor test and straight leg raising test: validity, responsiveness, and predictive value in patients with acute/subacute low back pain. Arch Phys Med Rehabil 2012;93:2210-5.
17. [17] Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clinical Psychology Review 1988;8:77-100.
18. [18] Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978;3:235-41.
19. [19] Moscato U, Poscia A, Gargaruti R, Capelli G, Cavaliere F. Normal values of exhaled carbon monoxide in healthy subjects: comparison between two methods of assessment. BMC Pulm Med 2014;14:204.
20. [20] Jones GT, Ratz T, Dean LE, Macfarlane GJ, Atzeni F. Disease severity in never smokers, ex-smokers, and current smokers with axial spondyloarthritis: results from the Scotland Registry for Ankylosing Spondylitis. Arthritis Care Res (Hoboken) 2017:69:1407-13.
21. [21] Zhang S, Li y, Xu X, Feng X, Yang D, Lin G. Effect of cigarette smoking and alcohol consumption on disease activity and physical functioning in ankylosing spondylitis: a cross-sectional study. Int J Clin Exp Med 2015;8:13919-27.
22. [22] Wang M, Wang S, Zhang X, Xia Q, Cai G, Yang X, et al. Analysis on the situation of subjective well-being and its influencing factors in patients with ankylosing spondylitis. Health Qual Life Outcomes. 2016;14:118.
23. [23] Kaan U, Ferda O. Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. Rheumatol Int 2005;25:357-60.
24. [24] Sakellariou GT, Anastasilakis AD, Kenanidis E, Potoupnis M, Tsiridis E, Savvidis M. The effect of smoking on clinical and radiographic variables, and acute phase reactants in patients with ankylosing spondylitis. Rheumatol Int 2015;35:2109-14.
25. [25] Chung HY, Machado P, van der Heijde D, D’Agostino MA, Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis 2012;71:809-16.
26. [26] Chen CH, Chen HA, Lu CL, Liao HT, Liu CH, Tsai CY et al. Association of cigarette smoking with Chinese ankylosing spondylitis patients in Taiwan: a poor disease outcome in systemic inflammation, functional ability, and physical mobility. Clin Rheumatol 2013;32:659-63.
27. [27] Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT. Smoking and Outcome in Ankylosing Spondylitis. Scand J Rheumatol 1996;25:138-42.
28. [28] Bodur H1, Ataman S, Rezvani A, Buğdaycı DS, Cevik R, Birtane M et al. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res 2011;20:543-9.
29. [29] Esen SA, Esen İ, Karabulut Y, Atmiş V. Effects of the disease characteristics and the treatment on psychological status in patients with rheumatoid arthritis and ankylosing spondylitis. Curr Rheumatol Rev 2017 Jul 28. doi: 10.2174/1573397113666170728123518.
30. [30] Park SJ, Kim JH, Pai KS, Shin JI. The link of HLA-B27 with interleukin-23/interleukin-17 axis in coexisting systemic lupus erythematosus and ankylosing spondylitis. Lupus 2011;20:1566.
31. [31] Jamalyaria F, Ward MM, Assassi S, Learch TJ, Lee M, Gensler LS, et al. Ethnicity and disease severity in ankylosing spondylitis: a cross-sectional analysis of three ethnic groups. Clin Rheumatol 2017;36:2359-64.